NeuroSense Financial Statements From 2010 to 2026

NRSNW Stock  USD 0.31  0.00  0.00%   
NeuroSense Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NeuroSense Therapeutics' valuation are provided below:
Earnings Share
(0.94)
There are over one hundred nineteen available fundamental ratios for NeuroSense Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check NeuroSense Therapeutics' last-minute fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable.
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 2.2 K, Depreciation And Amortization of 18.8 K or Interest Expense of 373.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.14. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with NeuroSense Stock
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

NeuroSense Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.2 M5.3 M2.8 M
Slightly volatile
Other Current Liabilities785.6 K788.9 K352.1 K
Slightly volatile
Total Current Liabilities1.5 M2.3 M706.4 K
Slightly volatile
Property Plant And Equipment Net134.4 K172.5 K64.9 K
Slightly volatile
Accounts Payable1.4 M1.3 M363.3 K
Slightly volatile
Cash4.1 M3.9 M2.2 M
Slightly volatile
Non Current Assets Total161.7 K198.9 K95.3 K
Slightly volatile
Non Currrent Assets Other20.3 K20.7 K29.8 K
Slightly volatile
Cash And Short Term Investments4.7 M3.9 M2.5 M
Slightly volatile
Net Receivables126 K188.6 K68.4 K
Slightly volatile
Common Stock Shares Outstanding12 M21.4 M8.7 M
Slightly volatile
Liabilities And Stockholders Equity5.2 M5.3 M2.8 M
Slightly volatile
Other Current Assets945.5 K989 K417.2 K
Slightly volatile
Other Stockholder Equity47.4 M45.1 M13.5 M
Slightly volatile
Total Liabilities2.1 M2.3 M962.4 K
Slightly volatile
Property Plant And Equipment Gross156.9 K241.5 K77.5 K
Slightly volatile
Total Current Assets5.1 M5.1 M2.7 M
Slightly volatile
Accumulated Other Comprehensive Income16.7 M28 M9.8 M
Slightly volatile
Common Stock800900982
Slightly volatile
Short and Long Term Debt Total62.4 K65.7 K1.3 M
Slightly volatile
Short Term Debt151.1 K167.9 K133.4 K
Slightly volatile

NeuroSense Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization18.8 K19.8 K736.9 K
Slightly volatile
Interest Expense373.3 K357.6 K165.4 K
Slightly volatile
Selling General Administrative3.5 M4.8 M1.8 M
Slightly volatile
Other Operating Expenses8.3 M11.4 M4.5 M
Slightly volatile
Research Development4.7 M6.6 M2.7 M
Slightly volatile
Total Operating Expenses8.3 M11.4 M4.5 M
Slightly volatile
Cost Of Revenue47.1 K25.3 K18.6 K
Slightly volatile
Selling And Marketing Expenses4.5 M5.1 M5.5 M
Slightly volatile

NeuroSense Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation476.2 K501.3 K1.2 M
Slightly volatile
Begin Period Cash Flow3.5 MM1.5 M
Slightly volatile
Capital Expenditures3.3 K3.5 K12 K
Pretty Stable
Total Cash From Financing Activities13.2 M12.5 M4.2 M
Slightly volatile
End Period Cash Flow4.1 M3.9 M2.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.150.164.1538
Slightly volatile
Payables Turnover0.140.160.1753
Slightly volatile
Cash Per Share0.20.210.2464
Slightly volatile
Days Payables Outstanding1.6 K1.8 KK
Slightly volatile
Income Quality0.470.890.5402
Slightly volatile
Net Debt To EBITDA0.370.380.7182
Very volatile
Current Ratio2.412.5416.7192
Slightly volatile
Capex Per Share1.0E-41.0E-40.0015
Very volatile
Interest Debt Per Share0.02260.02370.0409
Slightly volatile
Debt To Assets0.01740.01830.1202
Slightly volatile
Days Of Payables Outstanding1.6 K1.8 KK
Slightly volatile
Ebt Per Ebit1.01.190.9746
Very volatile
Quick Ratio2.412.5416.8624
Slightly volatile
Net Income Per E B T0.80.90.986
Slightly volatile
Cash Ratio1.851.9516.1506
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0245
Slightly volatile
Debt Ratio0.01740.01830.1202
Slightly volatile

NeuroSense Fundamental Market Drivers

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue25.3 K47.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.